MAGPLRAPLL
3
MAGPLRAPLL LLAILAVALA VSPAAGSSPG KPPR LVGGPM DASVEEEGVR R ALDFAVGEY NKASNDMYHS R ALQVVRARK QIVAGVNYFL DVELGRTTCT KTQPNLDNCP FHDQPHLKRK AFCSFQIYAV PWQGTMTLSK STCQDA 185 98 31 52 19 17 11 6 3 185 98 31 52 19 17 11 6 3 XY-C SF-07130508 # 229 R T: 12.08 AV: 1 N L: 1.25E 6 T: + c Full m s [400.00-2000.00] 400 600 800 1000 1200 1400 1600 1800 2000 m/z 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 R elative A bu ndan ce 830.9 455.5 774.8 945.7 495.1 832.6 572.9 737.8 1072.7 1174.2 1447.9 1223.8 1561.2 1720.0 1841.2 B A Score Expect Rank Peptide 52 0.0023 1 ASNDMYHSR 50 0.0041 1 ALDFAVGEYNK 78 9.5e - 006 1 LVGGP M DASVEEEGVR C LVGGP M DASVEEEGVR D MW Ctl ALS e 1 (Pasinetti et al., Online Supplement Data)
description
MAGPLRAPLL. LLAILAVALA. VSPAAGSSPG. KPPR. LVGGPM. DASVEEEGVR. R. ALDFAVGEY. NKASNDMYHS. R. ALQVVRARK. LVGGP. M. DASVEEEGVR. QIVAGVNYFL. DVELGRTTCT. KTQPNLDNCP. FHDQPHLKRK. AFCSFQIYAV. PWQGTMTLSK. STCQDA. figure 1 (Pasinetti et al., Online Supplement Data). A. B. - PowerPoint PPT Presentation
Transcript of MAGPLRAPLL
MAGPLRAPLL LLAILAVALA VSPAAGSSPG KPPRLVGGPM DASVEEEGVR RALDFAVGEY NKASNDMYHS R ALQVVRARK
QIVAGVNYFL DVELGRTTCT KTQPNLDNCP FHDQPHLKRK AFCSFQIYAV PWQGTMTLSK STCQDA
185
98
31
52
1917
11
6
3
185
98
31
52
1917
11
6
3
XY-CSF-07130508 #229 RT: 12.08 AV: 1 NL: 1.25E6T: + c Full ms [ 400.00-2000.00]
400 600 800 1000 1200 1400 1600 1800 2000
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Re
lativ
e A
bu
nd
an
ce
830.9
455.5
774.8 945.7495.1 832.6572.9 737.8 1072.7 1174.2 1447.91223.8
1561.2 1720.0 1841.2
BA
Score Expect Rank Peptide
52 0.0023 1 ASNDMYHSR
50 0.0041 1 ALDFAVGEYNK
78 9.5e - 006 1 LVGGP M DASVEEEGVR
C
LVGGP M DASVEEEGVR
D
MW Ctl ALS
figure 1 (Pasinetti et al., Online Supplement Data)
figure 2 (Pasinetti et al., Online Supplement Data)
10 20 30 40 50 60 MKALRLSASA LFCLLLINGL GAAPPGRPEA QPPPLSSEHK EPVAGDAVPG PKDGSAPEVR 70 80 90 100 110 120 GARNSEPQDE GELFQGVDPR ALAAVLLQAL DRPASPPAPS GSQQGPEEEA AEALLTETVR 130 140 150 160 170 180 SQTHSLPAAG EPEPAAPPRP QTPENGPEAS DPSEELEALA SLLQELRDFS PSSAKRQQET 190 200 210 220 230 240 AAAETETRTH TLTRVNLESP GPERVWRASW GEFQARVPER APLPPPAPSQ FQARMPDSGP 250 260 270 280 290 300 LPETHKFGEG VSSPKTHLGE ALAPLSKAYQ GVAAPFPKAR RAESALLGGS EAGERLLQQG 310 320 330 340 350 360 LAQVEAGRRQ AEATRQAAAQ EERLADLASD LLLQYLLQGG ARQRGLGGRG LQEAAEERES 370 380 390 400 410 420 AREEEEAEQE RRGGEERVGE EDEEAAEAAE AEADEAERAR QNALLFAEEE DGEAGAEDKR 430 440 450 460 470 480 SQEETPGHRR KEAEGTEEGG EEEDDEEMDP QTIDSLIELS TKLHLPADDV VSIIEEVEEK 490 500 510 520 530 540 RNRKKKAPPE PVPPPRAAPA PTHVRSPQPP PPPPSARDEL PDWNEVLPPW DREEDEVYPP 550 560 570 580 590 600 GPYHPFPNYI RPRTLQPPSA LRRRHYHHAL PPSRHYPGRE AQARHAQQEE AEAEERRLQE 610 QEELENYIEH VLLRRP
E
Control ALS0.0
2.5
5.0
7.5ControlALS
cyst
atin
C (
ug
/ m
l)
*
figure 3 (Pasinetti et al., Online Supplement Data)
